FermaVir releases positive oral bioavailability data for FV-100 shingles treatment

By Elaine Rigoli

Tampa, Fla., June 19 - FermaVir Pharmaceuticals, Inc. said new preclinical studies show that when its prodrug FV-100 is dosed orally, exceptional concentrations of active compound can be measured in the blood.

The company said these experiments showed that at the highest level of dosing required by the Food and Drug Administration in preclinical studies, levels of the active compound exceeded 50,000 times the EC50 for antiviral activity against varicella zoster, the causative virus for shingles.

The EC50 is a measure of the amount of a compound, which inhibits 50% of the virus in vitro.

The company said concentrations of the active compound remained well over 100 times the EC50 for over 72 hours after dosing.

FermaVir is an emerging biotechnology company located in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.